Camac Fund Amends Forte Bio 13D, Adds ATG Capital Contact
Ticker: FBRX · Form: SC 13D/A · Filed: Jan 5, 2024 · CIK: 1419041
Complexity: simple
Sentiment: mixed
Topics: shareholder-activism, insider-filing, ownership-change
TL;DR
**Camac Fund updated its Forte Bio 13D, adding a new contact, hinting at potential changes in their investment strategy.**
AI Summary
Camac Fund, LP, a significant shareholder in Forte Biosciences, Inc., has filed an Amendment No. 1 to its Schedule 13D, indicating a change in its beneficial ownership. The filing, dated January 3, 2024, updates the contact information for notices and communications to include Gabriel Gliksberg of ATG Capital Management alongside Eric Shahinian of Camac Partners, LLC. This suggests a potential collaboration or shift in the oversight of Camac Fund's investment in Forte Biosciences, which could influence future strategic decisions for the company. For investors, this matters because changes in major shareholder representation can signal upcoming activist involvement or a re-evaluation of the investment thesis, potentially impacting stock performance.
Why It Matters
This filing signals a potential shift in how a major shareholder, Camac Fund, LP, is managing its investment in Forte Biosciences, possibly indicating future strategic moves or increased oversight.
Risk Assessment
Risk Level: medium — Changes in major shareholder representation can lead to uncertainty regarding future company direction or activist pressure, posing a medium risk to current investors.
Analyst Insight
Investors should monitor future filings from Camac Fund, LP and Forte Biosciences, Inc. for any indications of increased shareholder activism or strategic changes, as the addition of a new contact from ATG Capital Management could signal a more active role.
Key Players & Entities
- Camac Fund, LP (company) — filing person and significant shareholder of Forte Biosciences, Inc.
- Forte Biosciences, Inc. (company) — the issuer of the securities
- Eric Shahinian (person) — contact person for Camac Partners, LLC
- Gabriel Gliksberg (person) — new contact person for ATG Capital Management
- ATG Capital Management (company) — firm associated with new contact person Gabriel Gliksberg
- $0.001 (dollar_amount) — par value per share of Forte Biosciences Common Stock
- January 3, 2024 (date) — date of event requiring the filing of this statement
Forward-Looking Statements
- Camac Fund, LP may increase its activist involvement in Forte Biosciences, Inc. given the addition of a new contact person from ATG Capital Management. (Forte Biosciences, Inc.) — medium confidence, target: Q2 2024
- The change in contact information could precede a strategic review or a change in investment strategy by Camac Fund, LP regarding its stake in Forte Biosciences, Inc. (Camac Fund, LP) — medium confidence, target: Q3 2024
FAQ
What is the purpose of this specific SC 13D/A filing?
This filing is Amendment No. 1 to the Schedule 13D previously filed by Camac Fund, LP, for Forte Biosciences, Inc. It updates information, specifically the contact person for notices and communications, adding Gabriel Gliksberg of ATG Capital Management alongside Eric Shahinian of Camac Partners, LLC, as of January 3, 2024.
Who are the primary entities involved in this filing?
The primary entities are Camac Fund, LP (the filing person), Forte Biosciences, Inc. (the issuer), Eric Shahinian of Camac Partners, LLC, and Gabriel Gliksberg of ATG Capital Management (the authorized persons to receive notices).
What is the CUSIP number for Forte Biosciences, Inc. common stock?
The CUSIP number for Forte Biosciences, Inc. Common Stock is 34962G109, as stated in the filing.
When was the event that required this amendment to be filed?
The date of the event which required the filing of this statement was January 3, 2024, according to the filing.
What is the par value of Forte Biosciences, Inc. Common Stock?
The par value of Forte Biosciences, Inc. Common Stock is $0.001 per share, as specified in the filing.
Filing Stats: 4,660 words · 19 min read · ~16 pages · Grade level 13.5 · Accepted 2024-01-05 17:27:26
Key Financial Figures
- $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
- $1,819,084 — ly owned by Camac Fund is approximately $1,819,084, including brokerage commissions. The a
- $1,825,572 — y owned by ATG Fund II is approximately $1,825,572, including brokerage commissions. The a
- $41,161 — McIntyre Partnerships is approximately $41,161, excluding brokerage commissions. Ite
Filing Documents
- formsc13da.htm (SC 13D/A) — 334KB
- ex99-3.htm (EX-99.3) — 40KB
- ex99-3_001.jpg (GRAPHIC) — 296KB
- ex99-3_002.jpg (GRAPHIC) — 357KB
- ex99-3_003.jpg (GRAPHIC) — 352KB
- ex99-3_004.jpg (GRAPHIC) — 331KB
- ex99-3_005.jpg (GRAPHIC) — 327KB
- ex99-3_006.jpg (GRAPHIC) — 339KB
- ex99-3_007.jpg (GRAPHIC) — 321KB
- ex99-3_008.jpg (GRAPHIC) — 337KB
- ex99-3_009.jpg (GRAPHIC) — 334KB
- ex99-3_010.jpg (GRAPHIC) — 330KB
- ex99-3_011.jpg (GRAPHIC) — 343KB
- ex99-3_012.jpg (GRAPHIC) — 382KB
- ex99-3_013.jpg (GRAPHIC) — 353KB
- ex99-3_014.jpg (GRAPHIC) — 364KB
- ex99-3_015.jpg (GRAPHIC) — 352KB
- ex99-3_016.jpg (GRAPHIC) — 337KB
- ex99-3_017.jpg (GRAPHIC) — 380KB
- ex99-3_018.jpg (GRAPHIC) — 351KB
- ex99-3_019.jpg (GRAPHIC) — 349KB
- ex99-3_020.jpg (GRAPHIC) — 364KB
- ex99-3_021.jpg (GRAPHIC) — 341KB
- ex99-3_022.jpg (GRAPHIC) — 303KB
- ex99-3_023.jpg (GRAPHIC) — 363KB
- ex99-3_024.jpg (GRAPHIC) — 362KB
- ex99-3_025.jpg (GRAPHIC) — 327KB
- ex99-3_026.jpg (GRAPHIC) — 354KB
- ex99-3_027.jpg (GRAPHIC) — 373KB
- ex99-3_028.jpg (GRAPHIC) — 350KB
- ex99-3_029.jpg (GRAPHIC) — 337KB
- ex99-3_030.jpg (GRAPHIC) — 358KB
- ex99-3_031.jpg (GRAPHIC) — 344KB
- ex99-3_032.jpg (GRAPHIC) — 329KB
- ex99-3_033.jpg (GRAPHIC) — 357KB
- ex99-3_034.jpg (GRAPHIC) — 337KB
- ex99-3_035.jpg (GRAPHIC) — 298KB
- ex99-3_036.jpg (GRAPHIC) — 305KB
- ex99-3_037.jpg (GRAPHIC) — 335KB
- ex99-3_038.jpg (GRAPHIC) — 312KB
- ex99-3_039.jpg (GRAPHIC) — 342KB
- ex99-3_040.jpg (GRAPHIC) — 285KB
- ex99-3_041.jpg (GRAPHIC) — 288KB
- ex99-3_042.jpg (GRAPHIC) — 51KB
- 0001493152-24-001610.txt ( ) — 19588KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete, and correct. Dated: January 5, 2024 CAMAC FUND, LP By: Camac Capital, LLC its General Partner By: /s/ Eric Shahinian Name: Eric Shahinian Title: Manager CAMAC PARTNERS, LLC By: Camac Capital, LLC its Managing Member By: /s/ Eric Shahinian Name: Eric Shahinian Title: Manager CAMAC CAPITAL, LLC By: /s/ Eric Shahinian Name: Eric Shahinian Title: Manager /s/ Eric Shahinian Eric Shahinian Individually and as attorney-in-fact for Michael G. Hacke ATG FUND II LLC By: ATG Capital Management, LLC Managing Member By: /s/ Gabriel Gliksberg Name: Gabriel Gliksberg Title: Managing Member ATG CAPITAL MANAGEMENT, LLC By: /s/ Gabriel Gliksberg Name: Gabriel Gliksberg Title: Managing Member /s/ GABRIEL GLIKSBERG GABRIEL GLIKSBERG 20 MCINTYRE PARTNERSHIPS, LP By: McIntyre Capital GP, LLC its General Partner By: /s/ Chris McIntyre Name: Chris McIntyre Title: Managing Member MCINTYRE CAPITAL GP, LLC By: